Modiano M R, Dalton W S, Lippman S M, Joffe L, Booth A R, Meyskens F L
Department of Internal Medicine, University of Arizona Cancer Center, Tucson.
Invest New Drugs. 1990 Aug;8(3):317-9. doi: 10.1007/BF00171846.
Retinoids, the natural and synthetic analogs of vitamin A, are growth-inhibiting and differentiation-inducing agents and show clinical promise as chemopreventive and antineoplastic agents. Fenretinide, a new synthetic retinoid, has antitumor activity in certain in vitro and in vivo model systems and was relatively nontoxic in phase I trials. Based on these data, we designed a phase II study of Fenretinide involving 31 patients with advanced breast cancer [15] and melanoma [16], two cancers shown to be responsive to this agent in preclinical models. Fenretinide was inactive in patients with advanced disease. Toxicity was mild, and reversible. Mucocutaneous side effects occurred in 16 (52%) patients. Nyctalopia developed in three patients one of whom developed decreased B-wave amplitude of the scotopic electroretinogram. The minimal toxicity and significant activity in preclinical studies make this an attractive agent for future breast cancer chemoprevention studies.
类视黄醇是维生素A的天然和合成类似物，是生长抑制和诱导分化剂，作为化学预防和抗肿瘤剂显示出临床应用前景。芬维A胺是一种新型合成类视黄醇，在某些体外和体内模型系统中具有抗肿瘤活性，在I期试验中相对无毒。基于这些数据，我们设计了一项芬维A胺的II期研究，涉及31例晚期乳腺癌患者[15]和黑色素瘤患者[16]，这两种癌症在临床前模型中显示对该药物有反应。芬维A胺对晚期疾病患者无效。毒性轻微且可逆。16例（52%）患者出现皮肤黏膜副作用。3例患者出现夜盲症，其中1例患者暗视视网膜电图的B波振幅降低。临床前研究中最小的毒性和显著的活性使其成为未来乳腺癌化学预防研究的有吸引力的药物。
